Log in
NASDAQ:REPL

Replimune Group News Headlines

$41.41
-1.01 (-2.38 %)
(As of 10/21/2020 12:00 AM ET)
Add
Compare
Today's Range
$37.23
Now: $41.41
$42.06
50-Day Range
$20.64
MA: $26.11
$42.42
52-Week Range
$8.58
Now: $41.41
$46.30
Volume1.00 million shs
Average Volume261,785 shs
Market Capitalization$1.67 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.23

Headlines

Replimune Group (NASDAQ REPL) News Headlines Today

Source:
DateHeadline
Replimune Group (NASDAQ:REPL) Upgraded to "Buy" at BidaskClubReplimune Group (NASDAQ:REPL) Upgraded to "Buy" at BidaskClub
marketbeat.com - October 22 at 2:19 AM
Replimune Group (NASDAQ:REPL) Upgraded to Hold at BidaskClubReplimune Group (NASDAQ:REPL) Upgraded to Hold at BidaskClub
marketbeat.com - September 1 at 7:24 AM
Replimune Group (NASDAQ:REPL) Downgraded by Zacks Investment ResearchReplimune Group (NASDAQ:REPL) Downgraded by Zacks Investment Research
marketbeat.com - August 13 at 7:02 AM
Zacks: Brokerages Expect Replimune Group Inc (NASDAQ:REPL) Will Announce Earnings of -$0.42 Per ShareZacks: Brokerages Expect Replimune Group Inc (NASDAQ:REPL) Will Announce Earnings of -$0.42 Per Share
americanbankingnews.com - October 20 at 7:21 PM
Replimune Appoints Tanya Lewis to the Board of DirectorsReplimune Appoints Tanya Lewis to the Board of Directors
finance.yahoo.com - October 19 at 7:01 PM
Comparing Cellectis (NASDAQ:CLLS) & Replimune Group (NASDAQ:REPL)Comparing Cellectis (NASDAQ:CLLS) & Replimune Group (NASDAQ:REPL)
americanbankingnews.com - October 18 at 1:13 PM
Replimune Group Inc (NASDAQ:REPL) Short Interest Up 35.8% in SeptemberReplimune Group Inc (NASDAQ:REPL) Short Interest Up 35.8% in September
americanbankingnews.com - October 17 at 5:35 PM
Replimune Group Inc (NASDAQ:REPL) Insider Pamela Esposito Sells 16,000 SharesReplimune Group Inc (NASDAQ:REPL) Insider Pamela Esposito Sells 16,000 Shares
americanbankingnews.com - October 16 at 8:40 PM
Replimune Group (NASDAQ:REPL) Trading Up 13% on Analyst UpgradeReplimune Group (NASDAQ:REPL) Trading Up 13% on Analyst Upgrade
americanbankingnews.com - October 15 at 6:18 PM
Replimune Group (NASDAQ:REPL) Price Target Raised to $44.00Replimune Group (NASDAQ:REPL) Price Target Raised to $44.00
americanbankingnews.com - October 15 at 10:25 AM
Barclays Boosts Replimune Group (NASDAQ:REPL) Price Target to $50.00Barclays Boosts Replimune Group (NASDAQ:REPL) Price Target to $50.00
americanbankingnews.com - October 15 at 9:44 AM
Replimune Group (NASDAQ:REPL) Price Target Raised to $51.00 at BMO Capital MarketsReplimune Group (NASDAQ:REPL) Price Target Raised to $51.00 at BMO Capital Markets
americanbankingnews.com - October 15 at 9:44 AM
Replimune Group (NASDAQ:REPL) Upgraded to Buy at HC WainwrightReplimune Group (NASDAQ:REPL) Upgraded to Buy at HC Wainwright
americanbankingnews.com - October 15 at 9:44 AM
Replimune Group (NASDAQ:REPL) PT Raised to $50.00Replimune Group (NASDAQ:REPL) PT Raised to $50.00
americanbankingnews.com - October 14 at 5:04 PM
Chardan Capital Boosts Replimune Group (NASDAQ:REPL) Price Target to $48.00Chardan Capital Boosts Replimune Group (NASDAQ:REPL) Price Target to $48.00
americanbankingnews.com - October 14 at 5:04 PM
Replimune Group (NASDAQ:REPL) Sets New 1-Year High at $31.25Replimune Group (NASDAQ:REPL) Sets New 1-Year High at $31.25
americanbankingnews.com - October 14 at 1:01 PM
Replimune Group (NASDAQ:REPL) Stock Price Up 6.9%Replimune Group (NASDAQ:REPL) Stock Price Up 6.9%
americanbankingnews.com - October 5 at 8:11 PM
Replimune Group Inc (NASDAQ:REPL) Short Interest UpdateReplimune Group Inc (NASDAQ:REPL) Short Interest Update
americanbankingnews.com - October 1 at 4:51 PM
Replimune Group (NASDAQ:REPL) Trading Up 8%Replimune Group (NASDAQ:REPL) Trading Up 8%
americanbankingnews.com - September 29 at 7:02 PM
Replimune Group IncReplimune Group Inc
bloomberg.com - August 22 at 8:31 AM
Replimune Group EPS beats by $0.01Replimune Group EPS beats by $0.01
seekingalpha.com - August 7 at 7:28 AM
Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate UpdateReplimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update
finance.yahoo.com - August 7 at 7:28 AM
Biodesix Appoints Jean Franchi and Hany Massarany to Board of DirectorsBiodesix Appoints Jean Franchi and Hany Massarany to Board of Directors
finance.yahoo.com - July 20 at 10:09 PM
Replimune Group, Inc. (REPL): Hedge Funds Are Reducing ExposureReplimune Group, Inc. (REPL): Hedge Funds Are Reducing Exposure
finance.yahoo.com - June 22 at 2:49 PM
Replimune (REPL) Looks Good: Stock Adds 5.8% in SessionReplimune (REPL) Looks Good: Stock Adds 5.8% in Session
finance.yahoo.com - June 11 at 10:01 AM
Replimune prices $100M share-offeringReplimune prices $100M share-offering
seekingalpha.com - June 9 at 7:26 AM
Replimune Announces Pricing of Upsized Public OfferingReplimune Announces Pricing of Upsized Public Offering
finance.yahoo.com - June 9 at 1:35 AM
BRIEF-Replimune Announces Proposed Public OfferingBRIEF-Replimune Announces Proposed Public Offering
www.reuters.com - June 8 at 8:35 PM
BRIEF-Replimune Group Entered Into Amendment No. 1 To Sales AgreementBRIEF-Replimune Group Entered Into Amendment No. 1 To Sales Agreement
www.reuters.com - June 8 at 8:35 PM
BRIEF-Replimune Reports Fiscal Q4 And Full Year 2020 ResultsBRIEF-Replimune Reports Fiscal Q4 And Full Year 2020 Results
www.reuters.com - June 3 at 10:28 PM
Replimune lead drug shows benefit in non-melanoma skin cancerReplimune lead drug shows benefit in non-melanoma skin cancer
seekingalpha.com - June 3 at 12:23 PM
BRIEF-Replimune Provides RP1 Data Update From Phase 2 Cohorts In Melanoma And Non-Melanoma Skin CancerBRIEF-Replimune Provides RP1 Data Update From Phase 2 Cohorts In Melanoma And Non-Melanoma Skin Cancer
www.reuters.com - June 3 at 12:23 PM
Replimune Provides RP1 Data Update from its Phase 2 Cohorts in Melanoma and Non-Melanoma Skin Cancer that Strongly Support Replimune’s Ongoing Registration-Directed Clinical Trials with RP1Replimune Provides RP1 Data Update from its Phase 2 Cohorts in Melanoma and Non-Melanoma Skin Cancer that Strongly Support Replimune’s Ongoing Registration-Directed Clinical Trials with RP1
finance.yahoo.com - June 3 at 7:22 AM
Replimune to Provide Data Update on June 3, 2020Replimune to Provide Data Update on June 3, 2020
finance.yahoo.com - April 30 at 7:45 AM
Replimune Appoints Dieter Weinand as Chairman and Paolo Pucci to the Board of DirectorsReplimune Appoints Dieter Weinand as Chairman and Paolo Pucci to the Board of Directors
finance.yahoo.com - April 2 at 7:30 AM
Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate UpdateReplimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update
finance.yahoo.com - February 13 at 9:15 AM
BRIEF-Replimune Provides 2019 Year End Corporate Update And Reviews Expected 2020 MilestonesBRIEF-Replimune Provides 2019 Year End Corporate Update And Reviews Expected 2020 Milestones
www.msn.com - January 13 at 4:55 PM
Replimune Provides 2019 Year End Corporate Update and Reviews Expected 2020 MilestonesReplimune Provides 2019 Year End Corporate Update and Reviews Expected 2020 Milestones
finance.yahoo.com - January 13 at 4:55 PM
BRIEF-Replimune Group- Robert Coffin Has Elected To Transition To Take Up Role Of President & Chief Research & Development OfficerBRIEF-Replimune Group- Robert Coffin Has Elected To Transition To Take Up Role Of President & Chief Research & Development Officer
www.msn.com - January 9 at 4:51 PM
Replimune revamps leadership teamReplimune revamps leadership team
seekingalpha.com - January 9 at 4:51 PM
Replimune Announces the Evolution of its Management Team as it Advances Through Later Stage Clinical Development and Prepares for CommercializationReplimune Announces the Evolution of its Management Team as it Advances Through Later Stage Clinical Development and Prepares for Commercialization
finance.yahoo.com - January 9 at 4:51 PM
Replimune to Present at the 38th Annual J.P.Morgan Healthcare ConferenceReplimune to Present at the 38th Annual J.P.Morgan Healthcare Conference
finance.yahoo.com - January 7 at 8:52 AM
Replimune Group, Inc. (NASDAQ:REPL): Are Hedge Funds Right About This Stock?Replimune Group, Inc. (NASDAQ:REPL): Are Hedge Funds Right About This Stock?
finance.yahoo.com - December 23 at 5:52 PM
Replimune appoints Jean M. Franchi as CFOReplimune appoints Jean M. Franchi as CFO
seekingalpha.com - December 9 at 1:57 PM
Replimune Group (REPL) Presents At Piper Jaffray31st Annual Healthcare Conference - SlideshowReplimune Group (REPL) Presents At Piper Jaffray31st Annual Healthcare Conference - Slideshow
seekingalpha.com - December 9 at 1:57 PM
Replimune Strengthens Executive Team with the Appointment of Jean Franchi as Chief Financial OfficerReplimune Strengthens Executive Team with the Appointment of Jean Franchi as Chief Financial Officer
finance.yahoo.com - December 9 at 8:57 AM
Replimune to Present at the Piper Jaffray 31st Annual Healthcare ConferenceReplimune to Present at the Piper Jaffray 31st Annual Healthcare Conference
finance.yahoo.com - November 26 at 8:06 AM
Replimune prices equity offering; shares up 3% premarketReplimune prices equity offering; shares up 3% premarket
seekingalpha.com - November 14 at 12:35 PM
Replimune Announces Pricing of Public OfferingReplimune Announces Pricing of Public Offering
finance.yahoo.com - November 14 at 7:32 AM
REPL Replimune Group, Inc. Common StockREPL Replimune Group, Inc. Common Stock
www.nasdaq.com - November 13 at 11:22 PM
Replimune Announces Proposed Public OfferingReplimune Announces Proposed Public Offering
finance.yahoo.com - November 12 at 6:55 PM
Replimune Group EPS misses by $0.01Replimune Group EPS misses by $0.01
seekingalpha.com - November 11 at 8:28 AM
Replimune Reports Second Fiscal Quarter Financial Results and Provides Corporate UpdateReplimune Reports Second Fiscal Quarter Financial Results and Provides Corporate Update
finance.yahoo.com - November 11 at 8:28 AM
This page was last updated on 10/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.